Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890786 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
A Early Phase 1 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 27
- Enrollment target
NCT00890786 is a Early Phase 1 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 27 participants.
The verdict
NCT00890786, a Early Phase 1 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The outcome for children with high-grade gliomas and diffuse intrinsic brainstem gliomas remains poor despite the use of multi-modal therapy with surgery, radiation therapy and chemotherapy.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-05 |
| Est. Completion | 2017-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00890786
The ClinicalTrials.gov registry entry for NCT00890786 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00890786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00890786 about?
NCT00890786 is a clinical study titled "A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas". The outcome for children with high-grade gliomas and diffuse intrinsic brainstem gliomas remains poor despite the use of multi-modal therapy with surgery, radiation therapy and chemotherapy.
What is the current status of trial NCT00890786?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 27 participants. The study started on 2009-05. Estimated completion is 2017-12.
What interventions are being tested in trial NCT00890786?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00890786?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.